Trial Profile
Pharmacokinetics, safety and tolerability of EDP 239 in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Mar 2016
Price :
$35
*
At a glance
- Drugs EDP 239 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Enanta Pharmaceuticals
- 23 Oct 2015 New trial record
- 18 Sep 2015 Results presented at Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy.